The Quantellect read.As of Nov 19, 2026, 8 active firms cover Sagimet Biosciences Inc. Series A Common Stock: 7 rate it Buy or better, 0 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $7.00 to $56.00 (about 8.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $26.46 sits 162% above the current $10.12. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-1.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy788%
Neutral00%
Sell113%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$26.46
+161.6% upside
Average target across 8 active firms as of Nov 19, 2026 vs $10.12 current
Highest Target$56.00
Average Target$26.46
Lowest Target$7.00
Detailed analyst forecasts for SGMT
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 7 of 8 active firms rate SGMT a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SGMT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.31 – $-0.22 · 5 analysts · -15% YoY
Next period, 5 analysts expect Sagimet Biosciences Inc. Series A Common Stock to earn $-0.28 a share (range $-0.31 – $-0.22), versus $-0.33 a year earlier. Full-year consensus is $-1.24, growing to $-1.45 the year after.
REVENUE · NEXT QUARTER
$2.0M
Range $0 – $5.0M · 5 analysts
Revenue is expected to reach $2.0M (range $0 – $5.0M). Full-year consensus is $0, rising to $3.6M next year.
Top analysts covering Sagimet Biosciences Inc. Series A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SGMT.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$27.00+166.9% to target
Overall win rate
43%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$32.00+216.4% to target
Overall win rate
44%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$56.00+453.6% to target
Overall win rate
44%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$67.00+562.4% to target
Overall win rate
30%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$29.00+186.7% to target
Overall win rate
38%
+ Follow
SGMT stock forecast FAQ
What is SGMT's average 12-month price target?+
The 8 active firms with a live target average $26.46 for Sagimet Biosciences Inc. Series A Common Stock over the next 12 months, ranging from a $56.00 high to a $7.00 low, as of Nov 19, 2026.
Is SGMT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SGMT?+
The Street-high target is $56.00 (Canaccord Genuity), and the Street-low is $7.00 (Goldman Sachs). The average of all 8 active-firm targets is $26.46.
How many active Wall Street firms cover SGMT?+
8 active firms have a recognized rating on Sagimet Biosciences Inc. Series A Common Stock as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SGMT?+
Among analysts who currently cover SGMT, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $27.00 target.
What is Sagimet Biosciences Inc. Series A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.31 – $-0.22) across 5 analysts. Full-year EPS is projected at $-1.24, rising to $-1.45 the following year.
How much revenue is Sagimet Biosciences Inc. Series A Common Stock expected to report next quarter?+
Consensus revenue is $2.0M (range $0 – $5.0M). Full-year revenue is projected at $0, growing to $3.6M next year.
Have analysts been upgrading or downgrading SGMT lately?+
As of Nov 19, 2026, 7 of 8 active firms rate SGMT a Buy (0 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SGMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.